Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab (MATCH Study)

Trial Profile

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab (MATCH Study)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Tabelecleucel (Primary)
  • Indications Lymphoproliferative disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms MATCH
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 02 Jan 2018 According to an Atara Biotherapeutics media release, three clinical sites have been opened for enrollment in the US.
    • 02 Jan 2018 Status changed from planning to recruiting according to an Atara Biotherapeutics media release.
    • 29 Dec 2017 According to an Atara Biotherapeutics media release, the company has received clearance from the US FDA to initiate this and another phase III study (ALLELE). The Phase 3 studies are expected to open for enrollment in the US imminently. Results from the first tabelecleucel Phase 3 study to reach the primary endpoint are expected to be announced in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top